Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
-
ORGANIZATION Industry Wants Continued Dialogue to Keep Price Maintenance Premium in Place: Janssen Japan Chief
September 13, 2017
-
REGULATORY MOF Budget Examiner Questions Price Maintenance Premium, Says Its Impact Amounts to Over 253 Billion Yen in FY2017
September 12, 2017
-
REGULATORY MHLW to Draft GL on Use of Real World Data in Application Filings to Promote Development of Drugs for Rare Diseases
September 12, 2017
-
ORGANIZATION Daiichi Sankyo’s Hirano to Replace Kamoya as Chuikyo Pharma Rep
September 11, 2017
-
ORGANIZATION Plasma Fraction Products Should Remain in List of Essential Drugs: Blood Products Association Exec
September 11, 2017
-
BUSINESS Pres. Fredrickson Leaves AZ Japan Unit after 14 Months in Office
September 11, 2017
-
REGULATORY Opdivo Clears MHLW Panel for 3rd Line Use in Gastric Cancer, Keytruda to Lose Sakigake Status
September 8, 2017
-
BUSINESS Chugai to Expand Range of Drugs on Its Medication Optimization Support Application
September 8, 2017
-
ACADEMIA AMED Study Group to Investigate Drugs to Recommend in Elderly Depression Patients; Findings to Be Reflected in New Guidelines
September 7, 2017
-
BUSINESS Spera Pharma Begins Business Capitalizing on “Takeda’s” Track Record, Aims to Become Japan’s No. 1 CDMO
September 6, 2017
-
ORGANIZATION JMA’s Imamura Questions Distribution Coefficient in Cost Calculation Formula
September 5, 2017
-
BUSINESS Mitsubishi Tanabe to Beef Up Marketing System in Field of Autoimmune Diseases, Plans to Expand Expert Sales Force
September 5, 2017
-
REGULATORY Spinraza Add’l Indication Reported to MHLW Panel, Setting Stage for Its Use in All SMA Patients
September 4, 2017
-
REGULATORY Programs Funded by MA Holder or Its Subsidiaries Subject to Regulations under Clinical Research Law
September 1, 2017
-
BUSINESS Daiichi Sankyo Denies Report on AZ’s Acquisition Offer
September 1, 2017
-
BUSINESS Daiichi Sankyo Share Trade Halted after Report on AZ’s Acquisition Offer
August 31, 2017
-
BUSINESS Fujifilm Holdings Aims to Achieve 500 Billion Yen in Healthcare Sales in FY2019
August 31, 2017
-
ACADEMIA Over 150 Clinical Trials of Epigenetic Drugs, Some with Novel Mechanisms of Action, Underway Worldwide
August 31, 2017
-
REGULATORY MHLW to Form Study Group to Address Leftover Vial Drug Issue, Weighs Multi-Dose Vials
August 30, 2017
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…